Novavax (DE:NVV1)
NASDAQ:NVV1
NVV1 Stock Chart & Stats
€7.45
-€1.01(-9.65%)
At close: 4:00 PM EST
€7.45
-€1.01(-9.65%)
Day’s Range― - ―
52-Week Range€5.34 - €10.03
Previous CloseN/A
Volume7.16K
Average Volume (3M)7.02K
Market Cap
€1.31B
Enterprise Value€1.63B
Total Cash (Recent Filing)€790.33M
Total Debt (Recent Filing)€295.06M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 12, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding164,438,130
10 Day Avg. Volume2,220
30 Day Avg. Volume7,020
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.07Price Target Upside48.53% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.4
Revenue Forecast (FY)€348.57M
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipsDeep, multi-year licensing agreements (e.g., Pfizer upfront and long-term royalty potential) convert Novavax’s Matrix-M and antigen platform into recurring, partner-funded development and commercialization streams. This reduces sole reliance on direct product sales and strengthens durable revenue optionality.
Partner-Driven Revenue GrowthSustained, material growth in partner-related revenue demonstrates the commercial viability of Novavax's technology and the ability to monetize via supply and licensing. Partner receipts are less volatile than single-market product sales and support predictable mid-term cash generation.
Strong Cash Runway & Non-dilutive FundingA large cash and AR base plus recent nondilutive inflows provide multi-quarter runway, lowering immediate refinancing risk. This funding buffer gives management time to convert MTAs, execute cost reductions, and pursue IND-enabling work without near-term equity dilution.
Bears Say
Negative Shareholders' EquityPersistently negative shareholders' equity limits financial flexibility and raises refinancing and dilution risk. In adverse conditions this structural weakness can force costly financing or accelerate dilution, constraining strategic options over the medium term.
Weak Cash GenerationOngoing negative operating and free cash flows indicate the business is still burning cash from operations. Even with partner receipts, sustained negative cash generation increases dependence on external funding or milestone receipts to sustain R&D and commercialization investments.
Dependency On MTA-to-License ConversionsRevenue and milestone realization hinge on partners converting MTAs into licenses; uncertain timelines mean anticipated partner milestones and royalties may be delayed. This dependency raises execution risk and could make projected partner revenues episodic rather than steadily recurring.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €5.34 and its highest was €10.03 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.31B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -€0.051 earnings per share for the quarter, beating the consensus estimate of -€0.206 by €0.155.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.34.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.051 in its last earnings report, beating expectations of -€0.206. Following the earnings report the stock price went up 18.955%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€11.07 (48.53% Upside)
€11.07 (48.53% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.92%
12-Months-Change
Fundamentals
Return on Equity
89.73%
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€11.07
▲(48.53% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Options Prices
Currently, No data available
---